1. Market Research
  2. > Healthcare
  3. > Pathology
  4. > Cancer Market Trends
  5. > Metastatic Lung Cancer-Pipeline Insights, 2016

Metastatic Lung Cancer-Pipeline Insights, 2016

  • November 2016
  • -
  • Delve Insight
  • -
  • 60 pages


DelveInsight’s, “ Metastatic Lung Cancer-Pipeline Insights, 2016”, report provides in depth insights on the pipeline drugs and their development activities around the Metastatic Lung Cancer. The DelveInsight’sReport covers the product profiles in various stages of development including Discovery, Pre-clinical, IND, Phase I, Phase II, Phase III and Preregistration. Report covers the product clinical trials information and other development activities including technology, licensing, collaborations, acquisitions, fundings, patent and USFDA & EMA designations details. DelveInsight’s Report also provides detailed information on the discontinued and dormant drugs that have gone inactive over the years for Metastatic Lung Cancer. DelveInsight’s Report also assesses the Metastatic Lung Cancer therapeutics by Monotherapy, Combination products, Molecule type and Route of Administration.

Please note:This report requires certain updates. We have all the information available but require 3 business days to complete the process and ensure it is as up-to-date as possible. Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated indication.

Scope
- The report provides competitivepipeline landscape of Metastatic Lung Cancer
- The report provides pipeline products under drug profile section which includes product description, MOA, licensors & collaborators, development partner and chemical information
- Coverage of the Metastatic Lung Cancer pipeline on the basis of target, MOA, route of administration, technology involved and molecule type
- The report reviews key players involved in the therapeutics development for Metastatic Lung Cancer and also provide company profiling
- The report also gives the information of dormant and discontinued pipeline projects
- Pipeline products coverage based on various stages of development ranging from preregistration till discovery and undisclosed stages
- Provides pipeline assessment by monotherapy and combination therapy products, stage of development and molecule type

Table Of Contents

Metastatic Lung Cancer-Pipeline Insights, 2016

Illustrative Table of contents

- Metastatic Lung Cancer Overview
- Metastatic Lung Cancer Pipeline Therapeutics
- Metastatic Lung Cancer Therapeutics under Development by Companies
- Metastatic Lung Cancer Filed and Phase III Products
- Comparative Analysis
- Metastatic Lung Cancer Phase II Products
- Comparative Analysis
- Metastatic Lung Cancer Phase I and IND Filed Products
- Comparative Analysis
- Metastatic Lung Cancer Discovery and Pre-Clinical Stage Products
- Comparative Analysis
- Drug Candidate Profiles
- Metastatic Lung Cancer - Therapeutics Assessment
- Assessment by Monotherapy Products
- Assessment by Combination Products
- Assessment by Route of Administration
- Assessment by Molecule Type
- Metastatic Lung Cancer - Discontinued Products
- Metastatic Lung Cancer - Dormant Products
- Companies Involved in Therapeutics Development for Metastatic Lung Cancer
- Appendix
- Methodology
- Contact Us
- Disclaimer

List of Tables

- Number of Products under Development for Metastatic Lung Cancer, 2016
- Number of Products under Development by Companies
- Comparative Analysis by Filed and Phase III Products, 2016
- Comparative Analysis Phase II Products, 2016
- Comparative Analysis Phase I and IND Filed Products, 2016
- Comparative Analysis Discovery and Pre-Clinical Stage Products, 2016
- Drug Candidates Profiles
- Metastatic Lung Cancer Assessment by Monotherapy Products
- Metastatic Lung Cancer Assessment by Combination Products
- Metastatic Lung Cancer Assessment by Route of Administration
- Metastatic Lung Cancer Assessment by Stage and Route of Administration
- Metastatic Lung Cancer Assessment by Molecule Type
- Metastatic Lung Cancer Assessment by Stage and Molecule Type
- Metastatic Lung Cancer Therapeutics - Discontinued Products
- Metastatic Lung Cancer Therapeutics - Dormant Products
- Products under Development by Companies, 2016

List of Figures

- Number of Products under Development for Metastatic Lung Cancer, 2016
- Filed and Phase III Products, 2016
- Phase II Products, 2016
- Phase I and IND Filed Products, 2016
- Discovery and Pre-Clinical Stage Products, 2016
- Metastatic Lung Cancer Assessment by Monotherapy Products
- Metastatic Lung Cancer Assessment by Combination Products
- Metastatic Lung Cancer Assessment by Route of Administration
- Metastatic Lung Cancer Assessment by Stage and Route of Administration
- Metastatic Lung Cancer Assessment by Molecule Type
- Metastatic Lung Cancer Assessment by Stage and Molecule Type

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
Lung Cancer: Analytical Tool

Lung Cancer: Analytical Tool

  • $ 8096
  • Industry report
  • August 2016
  • by Bioseeker

Analytical Tools are cancer area specific intelligence and surveillance toolkits within a select number of hot, emerging cancer therapy areas. They are designed to empower biotech/pharma professionals ...

Market Access Impact: Non-Small Cell Lung Cancer (EU5) 2016

Market Access Impact: Non-Small Cell Lung Cancer (EU5) 2016

  • $ 5390
  • Industry report
  • September 2016
  • by Firstword Pharma

Prescription barriers hurt 5 of the 9 brands we surveyed. Is your brand losing market share? In the EU5, one of the most prescribed NSCLC drugs is stuck in 2nd place due to the biggest barrier-related ...

Market Access Impact: Non-Small Cell Lung Cancer (US) 2016

Market Access Impact: Non-Small Cell Lung Cancer (US) 2016

  • $ 5390
  • Industry report
  • September 2016
  • by Firstword Pharma

7 of the 10 brands we surveyed lose share due to market barriers. Is your brand one of them? In the US, market barriers are causing 7 of the 10 NSCLC drugs we surveyed to lose market share. What’s ...


Download Unlimited Documents from Trusted Public Sources

Cancer Statistics in the UK

  • November 2016
    10 pages
  • Cancer  

  • United Kingdom  

View report >

Pollution Control Statistics in the US

  • November 2016
    218 pages
  • Pollution Contr...  

    Cancer  

    Metals  

  • United States  

    North America  

View report >

Cancer Statistics in the UK

  • November 2016
    15 pages
  • Cancer  

  • United Kingdom  

View report >

Related Market Segments :

Lung Cancer

ref:plp2016

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.